Study finds WNTinib delays hepatoblastoma tumor growth in mice and enhances survival rates, targeting CTNNB1 mutation.

A study has revealed that WNTinib, a new drug, effectively delays tumor growth and enhances survival rates in mice with hepatoblastoma, a liver cancer affecting children. Targeting a specific mutation (CTNNB1) associated with the cancer, WNTinib shows promise in treating this condition while minimizing damage to healthy cells. Researchers emphasize the need for further studies to clarify the drug's mechanisms and improve its safety for potential human use.

October 22, 2024
4 Articles